Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · AdaptHealth (AHCO)

AdaptHealth Q2 revenue rises 12.7% to $740.3M; cuts 2026 adjusted EBITDA outlook

Mixed Impact 4 of 5 guidance Written later

AdaptHealth reported second-quarter 2026 net revenue of $740.3 million, up 12.7% from a year earlier, but recorded a $144.2 million goodwill impairment and a net loss attributable to the company. The company also lowered its fiscal 2026 adjusted EBITDA guidance to $490 million to $520 million from $680 million to $730 million, citing a West Coast capitated contract, a manufacturer price increase and portfolio changes, which weighs on shareholders' earnings outlook.

Key points

  • Q2 net revenue was $740.3 million versus $657.1 million, an increase of 12.7%; organic revenue grew 15.9%.
  • Goodwill impairment of $144.2 million drove a net loss; adjusted EBITDA was $132.0 million versus $136.4 million, down 3.2%.
  • Fiscal 2026 adjusted EBITDA guidance is $490 million to $520 million; the revision includes a $100 million impact from the Diabetes Health discontinued operations, a $55 million West Coast contract impact and a $30 million manufacturer pric
  • AdaptHealth agreed in July 2026 to sell its Diabetes Health business for $235.0 million in cash, subject to customary purchase price adjustments.

The filing

CompanyAdaptHealth (AHCO)
Form8-K, current report
Filed with the SECAug 4, 2026, 7:09 AM ET
Accession number0001628280-26-052149

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.